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Abstract Considerable differences exist amongst coun-
tries in the mutation probability methods and thresholds
used to select patients for BRCA1/2 genetic screening. In
order to assess the added value of mutation probability
methods, we have retrospectively calculated the BRC-
APRO and Myriad II probabilities in 306 probands who
had previously been selected for DNA-analysis according
to criteria based on familial history of cancer. DNA-
analysis identiﬁed 52 mutations (16.9%) and 11 unclas-
siﬁed variants (UVs, 3.6%). Compared to cancer history, a
threshold C10% with BRCAPRO or with Myriad II
excluded about 40% of the patients from analysis,
including four with a mutation and probabilities \10%
with both programs. All four probands had a BRCA2
mutation. BRCAPRO and Myriad II showed similar
speciﬁcity at 10% threshold, overall BRCAPRO was more
sensitive than Myriad II for the detection of mutations.
Only two of the probands with an UV had probabilities
[20% with BRCAPRO and Myriad II. In summary,
BRCAPRO and Myriad II are more efﬁcient than cancer
history alone to exclude patients without a mutation.
BRCAPRO performs better for the detection of BRCA1
mutations than of BRCA2 mutations. The Myriad II scores
provided no additional information than the BRCAPRO
scores alone for the detection of patients with a mutation.
The use of thresholds excluded from analysis the majority
of patients carrying an UV.
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The two major susceptibility genes for breast cancer (BC)
and ovarian cancer (OC), BRCA1 (MIM: 113705) and
BRCA2 (MIM: 600185) were discovered in 1994 and 1995,
respectively [1, 2]. Initially, the Protein Truncation Test
(PTT) was the screening method widely used as a quick
and inexpensive test to detect pathogenic truncating
mutations in these genes. At a later stage, the screening was
optimised using denaturing high performance liquid chro-
matography (DHPLC) [3], direct sequencing and Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA) [4], in
which all types of mutations or deletions could be detected.
A drawback of this optimised screening methodology is
that, as compared to PTT, it is laborious and more
expensive. Furthermore, inherited mutations in these two
genes only account for a small fraction of the familial
clustering of BC and OC in the total group of index patients
[5–9]. Therefore, accurate selection criteria for patients
eligible for DNA-analysis are mandatory.
Various risk prediction algorithms and models have
been developed to identify putative BRCA1/2 mutation
carriers. The ﬁrst published model was that of the Uni-
versity of Pennsylvania (U-Penn), also called the Couch
model [10]; followed by Shattuck-Eidens model or Myriad
I[ 11]; Myriad II, an extension of the previous model [12];
the Myriad tables by Frank et al. [13]; the BRCAPRO
model [14]; the Manchester scoring system of Evans et al.
[15] and the recent BOADICEA model of Antoniou et al.
[16].
In addition to the different types of models, also the
thresholds used in these models to establish the indica-
tion to perform DNA-analysis, vary substantially among
countries. In 1996, the American Society of Clinical
Oncology recommended that consideration of BRCA1/2
testing should be offered to patients with strong familial
features, such as BC in the family or very early age at
onset of the disease, c.q. corresponding to those patients
whose prior probability of carrying a mutation exceeds
10% [17]. However, the updated American guidelines in
2003 did not recommend a numerical threshold [18].
Currently, the majority of Dutch Cancer Genetics Ser-
vices apply a 10% pre-test probability as threshold to
perform DNA analysis of the BRCA1 and BRCA2 genes
[19], whereas in the UK most centres offer mutation
analysis to families with a 20% or greater pre-test prob-
ability of carrying a mutation [20].
The goal of our study was to retrospectively analyze the
added value of predictive mutation probability scores and
optimal thresholds in terms of sensitivity and speciﬁcity of
two currently used mutation probability models BRCAP-
RO and Myriad II, in a group of patients prior selected on
the basis of family history of cancer.
Materials and methods
Patients and DNA-analysis
Our study includes 306 probands who had been selected for
DNA-analysis based on established criteria about personal
and family cancer history (shown in Table 1).
In the period 1996–2000 partial mutation screening of
the BRCA1 and BRCA2 genes was performed using the
protein truncation test (PTT). The PTT was used only for
exon 11 of BRCA1 and exons 10 and 11 of BRCA2. From
2000 on, complete genetic screening was performed using
DHPLC [3], direct sequencing and for BRCA1 also MLPA
[4].
Clinical data of all the probands and their ﬁrst and
second degree relatives were retrieved from their medical
records, which included cancer site: BC and/or OC, bilat-
eral BC, BC in male relatives, age at diagnosis and number
of affected relatives (data not shown). All probands were
affected with breast cancer and/or ovarian cancer. There
were no probands with known Jewish ancestry.
Mutation probability methods
BRCAPRO [14] is a Mendelian model that incorporates
mutated allele frequencies and cancer speciﬁc penetrances,
in addition to the following clinical data about the probands
and ﬁrst and second degree relatives: number of women
affected with BC; OC only; discrimination between
paternal and maternal inheritance pattern; BC under age 50
and OC; bilateral BC; relative with both OC and BC;
affected and unaffected individuals; Ashkenazi Jewish
ancestry and male BC.
The Myriad II prevalence tables [12] are based on pro-
band and family history accompanying results of BRCA1/2
deleterious variant samples tested by the Myriad company.
Table 1 Indications for DNA-analysis based on cancer history
(classiﬁed by number of affected relatives)
Number of affected
relatives
Indication for performing DNA-analysis
1aB C \35 years
b Bilateral BC; ﬁrst time\50 years
c Male BC
dO C \50 years
2 a Two-ﬁrst degree relatives with BC/OC,
one case\50 years
b Two-ﬁrst degree relatives with OC
c Two-second degree relatives
with BC/OC, both\50 years
C3 Three or more affected relatives in the family
BC Breast cancer, OC Ovarian cancer
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123The calculation takes into account if there are relatives who
have been diagnosed with OC at any age, if relatives have
been diagnosed with BC, grouped by those over and under
age 50 years at diagnosis of BC, and the presence of male
BC. It does not take into account bilateral BC and speciﬁc
age at diagnosis. In addition, it only allows inclusion of a
maximum of three relatives, including the patient; and it
does not calculate BRCA1 and BRCA2 mutation probabil-
ities separately like BRCAPRO. A more detailed descrip-
tion of both models has been published [12–14].
Carrier probabilities with BRCAPRO and Myriad II
were calculated with the CancerGene software package
from the University of Texas Southwestern Medical Center
(CaGene version 4.0). Additional information about Can-
cerGene is available at http://www.utsouthwestern.edu.
Statistical analysis
We calculated the carrier probabilities using the BRCAP-
RO and Myriad II models and compared the clinical
characteristics between the group of probands with and
those without a pathogenic mutation. Carriers of UVs were
reported separately and not included in either the mutation
positive or mutation negative groups for the purpose of the
analysis of clinical features. Genetic alterations reported as
polymorphisms were scored as mutation negatives. All data
were analyzed using SPSS statistical software version 15.0
for Windows. The sensitivity, speciﬁcity, positive and
negative predictive values, and positive and negative
likelihood ratios were calculated for both BRCAPRO and
Myriad II, and each of them for 10 and 20% thresholds.
Receiver operating characteristic (ROC) curves were
drawn and the areas under the curve (AUC) were calcu-
lated in the group of 295 probands with either a mutation or
a wild-type genotype. Calculations were made for BRC-
APRO and for Myriad II and within each of them at 10 and
20% thresholds.
Results
DNA-analysis
Our study included a total of 306 probands who were eli-
gible for BRCA1 and BRCA2 mutation detection, based on
established personal and family cancer history criteria, as
shown in Table 1. With the PTT we found 20 pathogenic
mutations (6.8%). In the remaining 286 probands, complete
BRCA1 and BRCA2 gene sequencing showed 43 additional
genetic variations (14%). Thirty-two of them (10.4%)
could be classiﬁed as a pathogenic mutation (BRCA1
n = 13, BRCA2 n = 19). The remaining 11 variants
(3.6%) were classiﬁed as unclassiﬁed variants (UVs,
BRCA1 n = 7, BRCA2 n = 4). Figure 1 summarizes the
chronological sequence of diagnostic methods and selec-
tion criteria applied in the studied population. An indi-
vidual description of the genetic variants identiﬁed is
presented in Table 2. Instructions for the nomenclature
for the sequence variations can be seen at: http://www.
genomic.unimelb.edu.au/mdi/mutnomen/recs.html.
Classiﬁcation of the genetic variants (mutations or UVs)
was done according to the Breast Cancer Information Core
(BIC) database: [http://research.nhgri.nih.gov/bic/].
Mutation probabilities
Pathogenic mutations
The mean carrier probabilities with BRCAPRO and Myriad
II for the groups with a mutation and without a mutation
are shown in Table 3. The probability scores are also
shown for the subgroup of patients with mutations detected
with PTT and for those with mutations detected by com-
plete analysis. The carrier probabilities of the probands
with a mutation (n = 53) were signiﬁcantly higher than
those without a mutation, in both models (BRCAPRO:
P\0.0001, Myriad II: P\0.0001). Apart from BRC-
APRO and Myriad II, the occurrence of OC in the family
(P = 0.001) was the only clinical parameter which was
signiﬁcantly associated with the presence of a BRCA1/2
mutation (data not shown).
The performance of the models, at 10 and 20% thresh-
olds, is presented in Table 4 and Fig. 2 shows the corre-
sponding ROC curves. Using 10% threshold with
BRCAPRO 110 probands had a probability\10% of whom
four had a mutation. With Myriad, nine out of 126 probands
Fig. 1 Chronological sequence of events in the study population
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123with a probability,\10% had a mutation. The four probands
missed with BRCAPRO were also missed with Myriad.
These four probands carried a BRCA2 mutation, none of
themhadafamilyhistoryofmaleBC,OCorbilateralBC.In
onecasetheindicationforDNAanalysiswasthreeBCcases
in the family (indication 3, Table 1). The other three cases
have a family history of two BC cases with one case below
age 50 (indication 2a, Table 1).
Results using the 20% threshold, 7 out of 160 probands
with BRCAPRO and 18 out of 249 probands with Myriad
II had a mutation with a probability below the threshold. At
both thresholds BRCAPRO is more sensitive than Myriad
II, at 10% they both have similar speciﬁcity while at 20% is
Myriad II more speciﬁc (Table 4). As shown by the four
AUC calculations from Fig. 2: (a) BRCAPRO performed
better than Myriad II at both thresholds and (b) the AUC
for the 20% thresholds were better than 10% thresholds.
Unclassiﬁed variants
The group of 11 UVs had median mutation probabilities
with BRCAPRO of 13.6% (range 0.3–97.3%) and with
Myriad II of 17.4% (range 7.3–37.6%). When compared
with the group with a mutation, the UVs had lower prob-
abilities than the group with a mutation: with BRCAPRO
were statistically signiﬁcant (P = 0.004), with Myriad II
Table 2 Genetic variants identiﬁed
BRCA1 BRCA2
Exon Nucleotide change Number
of families
Exon Nucleotide change Number
of families
Pathogenic mutations found with PTT
11 c.2193_2197del5 5 11 c.5213_5216del4 1
11 c.2722G[T 4 11 c.5645C[G1
11 c.1291_1292insT 1 11 c.5682C[G1
11 c.2646_2648delTGC 1 11 c.6275_6576delTT 1
11 c.2685_2686delAA 1 11 c.6396_6397insA 1
11 c.2989_2990insAA 1 11 c.6486_6489del4 1
11 c.6643delA 1
Total 6 13 Total 7 7
Pathogenic mutations found with DHPLC, MLPA, and sequencing
1 del ex1a/b-2 1 3 c.115delG 1
2 c.68_69delAG 2 5 c.469_470delAA 2
5 c.191G[A 1 6 c.516 ? 1G[T1
8 c.514C[T 1 8 c.658_659delGT 2
17 c.4987- ?_2074 ? ?del 1 10 c.1773-1776del4 1
18 c.5080G[T 1 10 c.1813insA 1
20 c.5277 ? 1G[A 4 11 c.4314delC 1
22 c.5346G[A 1 15 c.7436_7437-2delAGAT 1
24 c.5503C[T 1 16 c.7734_7740del6ins9 2
18 c.8058_8059delT 3
19 c.8374_8384del11ins3 1
23 c.9063_9078del16 1
23 c.9117G[A2
Total 9 13 Total 13 19
Unclassiﬁed variants
11 c.692C[T 1 10 c.1385A[G1
11 c.1258G[T 1 15 c.7469T[C1
11 c.1486C[T 1 18 c.8111C[T1
17 c.4987-3C[G 1 21 c.8723T[G1
19(I) c.5194-25A[C1
20 c.5216A[G1
23 c.5435C[G1
Total 7 7 Total 4 4
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123Table 3 BRCAPRO and Myriad II scores of BRCA mutation positive versus negative populations
Mutations with PTT
N = 21
Mutations with
complete analysis
N = 32
Total mutations
N = 53
No mutation
N = 243
P values (*)
BRCAPRO M
±SD
Range
0.699
(± 0.248)
0.186–0.997
0.586
(± 0.339)
0.012–1.00
0.629
(± 0.310)
0.012–1.00
0.240
(± 0.273)
0.001–0.994
\0.0001
Myriad II M
±SD
Range
0.293
(± 0.124)
0.122–0.465
0.202
(± 0.126)
0.019–0.421
0.237
(± 0.131)
0.019–0.465
0.119
(± 0.102)
0.007–0.603
\0.0001
Results expressed as: M ± SD mean (± standard deviation)
(*) P values: total mutations versus no mutations: t test
Table 4 Performance parameters of BRCAPRO and Myriad II
Threshold 10% Threshold 20%
BRCAPRO Myriad II BRCAPRO Myriad II
Mutations/probands below threshold (*) 4/110 9/126 7/160 18/249
Sensitivity (95% CI) 0.875 (0.760–0.990) 0.719 (0.563–0.875) 0.781 (0.638–0.925) 0.438 (0.266–0.609)
Speciﬁcity (95% CI) 0.433 (0.372–0.494) 0.476 (0.415–0.538) 0.602 (0.542–0.663) 0.909 (0.874–0.945)
Positive predictive value (95% CI) 0.163 (0.108–0.218) 0.147 (0.092–0.203) 0.198 (0.129–0.268) 0.378 (0.222–0.535)
Negative predictive value (95% CI) 0.965 (0.931–0.999) 0.931 (0.887–0.974) 0.956 (0.925–0.988) 0.928 (0.896–0.960)
(*) Number of probands with a mutation/total number of probands below the thresholds (i.e.,\10% or\20%)
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123did not achieve statistical signiﬁcance (P = 0.093) (data
not shown).
As shown in Table 5, with Myriad II nine UVs and with
BRCAPRO seven of the 11 UVs had mutation probabilities
below 20%. The UVs: c.4987-3C[G (putative splice var-
iant), and c.5216A[Gi nBRCA1 were the only two UVs
with probability values [20% both with BRCAPRO and
Myriad II.
Discussion
This study included 306 probands who had prior been
selected for DNA-analysis of BRCA1 and BRCA2 muta-
tions based on cancer history criteria. From 1995 until
2000, the PTT was the widely used quick, inexpensive
detection technique, which at that time resulted in the
detection of a mutation in 20 unrelated patients. At a later
stage, complete sequencing analysis of the coding regions
including intron–exon boundaries was performed, which
resulted in the identiﬁcation of an additional 43 genetic
variations in individual probands of which 32 were path-
ogenic and 11 unclassiﬁed (UV). We then performed a
retrospective study to estimate the mutation probabilities
using BRCAPRO and Myriad II in all cases.
Concerning mutation detection rate, our results are in
line with previous reports ([21] which show that complete
BRCA1/2 analysis substantially increases the number of
variations detected as compared to PTT alone. However, it
is less obvious which methods and which thresholds to use
for selecting the patients for DNA-analysis. In this respect,
the right balance between costs and mutation coverage
needs to be determined: obviously, the ideal method has a
high sensitivity, a high speciﬁcity and a high negative
predictive value.
We found in our population study that BRCAPRO and
Myriad II are more speciﬁc than cancer history, since they
both excluded from analysis about 40% of the patients who
did not have a mutation. Looking at sensitivity, BRCAPRO
was more sensitive than Myriad II which is in line with
previous publications by Berry et al. [18, 22]. Overall
BRCAPRO performed better than Myriad II, as shown by
their ROC curves.
Several groups have compared risk prediction models
among each other [22–26]. Both Antoniou et al. [25] and
Lindor et al. [26] compared performance of various carrier
prediction algorithms, including BRCAPRO and Myriad II.
In the study of Lindor et al. (26) no a priori selection
criteria were required to perform DNA-testing. All models
tested performed reasonably well. In the study of Antoniou
et al. [25], with 1,934 families the largest published so far,
families in whom DNA-testing had been performed were
supplied by the clinical genetics centres and from research
studies. The indication criteria used to perform DNA-
analysis in those settings are not speciﬁed. The authors
show that BOADICEA provided the best discrimination of
the ﬁve algorithms analyzed, though no signiﬁcant differ-
ences were observed with this model and BRCAPRO. Both
studies [25, 26] concluded that these prediction models
under-predicted the numbers of carriers in the low esti-
mated risk category. However, none of these studies have
compared the added value of the use of quantitative
methods, i.e., scores obtained with mutation probability
detection methods to qualitative criteria based on cancer
family history as indication for DNA analysis.
About the thresholds, the AUCs were better at 20% than
at 10%, which also indicates the preference from an eco-
nomic point. However, from a clinical point of view sen-
sitivity is more important than speciﬁcity, which means
that a choice has to be made between sparing 16% of the
total of tests performed (i.e., 50 probands with mutation
probabilities between 10 and 20% with BRCAPRO) at the
price of missing three probands with a mutation.
Noteworthy is that the four pathogenic mutations that
were missed with BRCAPRO, were also four of the nine
which were missed with Myriad II using the 10% threshold
and that all four are located in the BRCA2 gene. This sug-
gests that for detection of BRCA1 mutations, BRCAPRO at
a threshold of 10% is the method of choice: i.e., it has the
same sensitivity as the cancer history criteria and reduces
the number of tests by 40%. The fact that these probability
models have a better performance for BRCA1 than BRCA2
has been reported previously by James et al. [23] and
Bodmer et al. [24], and is related to the lower penetrance of
the mutations in BRCA2. Indeed, as explained in the results
section, none of the families of these patients included any
of the most characteristic features of the BRCA families,
such as OC, bilateral BC or male BC.
An additional advantage of the use of models with
thresholds is the exclusion of many patients carrying an
UV. Indeed, since the majority of the UVs that have been
detected and reported in the literature are later reclassiﬁed
as neutral variants [27], a speciﬁc method is also desirable
which can selectively exclude those UVs which are not
clinically relevant. We have previously reported that
patients with a pathogenic mutation have signiﬁcantly
higher a priori probabilities with BRCAPRO and Myriad II
than those with a UV [28], which also suggests that most of
the UVs are neutral variants. In addition, BRCAPRO and
Myriad II have been shown to be useful parameters also to
predict whether a UV is deleterious when used in multi-
parametric regression models [29].
Interestingly, from the two UVs with mutation proba-
bilities above 20% with BRCAPRO and Myriad II, the
p.D1739G variant in BRCA1 has been classiﬁed as cancer-
associated in the literature according to criteria, such as
BRCA1/2 mutation probability thresholds 199
123polarity change, conservation amongst species and in silico
models [30]. Conversely, for most of those UVs with a
mutation probability below 20%, evidence from other
sources also argue against them being deleterious. This
is the case for: p.R496C in BRCA1 [31, 32] and p.E462G
[29, 33, 34] and p.V2908G [34]i nBRCA2.
In conclusion, BRCAPRO and Myriad II probability
scores allow exclusion of a large proportion of mutation
negative probands for BRCA1/2 diagnosis, as compared to
using familial cancer history alone. When comparing the
two models, BRCAPRO is more sensitive in detecting
known pathogenic mutations than Myriad II. Myriad II
scores provide no added value to BRCAPRO alone. BRC-
APRO performs better for the identiﬁcation of patients with
a BRCA1 than with a BRCA2 mutation. The use of quanti-
tative scores exclude from study a considerable number of
patients carrying an UV. Information about the probability
scores may be also valuable for the classiﬁcation of UVs.
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